← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Prolx Pharmaceuticals, Lp
Pittsburgh, PA
$3,511,959
Total funding
6
Grants
Funding mix
By agency
NIH$3,511,959 · 6
By mechanism
R44$2,556,620 · 2
R43$825,339 · 3
R41$130,000 · 1
Investigators at Prolx Pharmaceuticals, Lp
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
NOVEL ANTITUMOR DISULFIDES$698,662
R44 · FY2000 · CA
NOVEL ANTITUMOR DISULFIDES$654,041
R44 · FY2002 · CA
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy$648,754
R44 · FY2002 · CA
NOVEL ANTITUMOR DISULFIDES$438,319
R44 · FY2001 · CA
CELLECTARRAY FOR CANCER DRUG DEVELOPMENT$259,028
R43 · FY2000 · CA
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS$251,384
R43 · FY2001 · CA
UNIQUE THIOREDOXIN INHIBITORS AS ANTI-CANCER DRUGS$188,860
R43 · FY2001 · CA
VALIDATION AND OPTIMIZATION OF TUBULIN TARGETED DRUGS$130,000
R41 · FY2000 · CA
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS$126,067
R43 · FY2002 · CA
NOVEL ANTITUMOR DISULFIDES$116,844
R44 · FY2002 · CA